Download Supplementary Information

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Green fluorescent protein wikipedia , lookup

Amitosis wikipedia , lookup

Cellular differentiation wikipedia , lookup

List of types of proteins wikipedia , lookup

JADE1 wikipedia , lookup

Artificial gene synthesis wikipedia , lookup

Transcript
Gentile el al., Supplementary Information
Table of Contents
Supplementary Results ......................................................................................................................... 1
Setup of a novel gene trapping strategy ........................................................................................... 1
Rationale ...................................................................................................................................... 1
Construction and validation of trapping vectors .......................................................................... 1
Methods ........................................................................................................................................ 3
Mapping of trap integration sites by RAN-PCR .............................................................................. 4
Rationale ...................................................................................................................................... 4
Methods ........................................................................................................................................ 4
Supplementary References ................................................................................................................... 5
Supplementary Results
Setup of a novel gene trapping strategy
Rationale
We conceived a functional genomics approach to the study of invasive growth by identifying genes
that are transcriptionally regulated by HGF in vitro in the MLP-29 mouse embryo liver cell line
(Medico et al. 1996). Such genes are likely to be involved in the control of invasive growth and thus
may directly contribute to the invasive-metastatic phenotype of neoplastic cells. Our approach
entailed a strategy based on gene trapping. Gene trapping exploits random integration of vectors
carrying a reporter gene not preceded by a promoter, to generate reporter cell clones displaying the
transcriptional activity of virtually any gene in the genome. We have previously developed a vector
for systematic trapping of transcriptionally regulated genes, ROSA-GFNR (Medico et al. 2001),
that, for positive selection of traps in expressed genes requires cell sorting, a time-consuming and
technically challenging procedure. To overcome this limit, we designed a new selectable reporter
gene, named PGN after the derivation from a fusion of three components: puromycin resistance
(PuroR), GFP and E. coli Nitroreductase (NTR). The PuroR component brings the key innovation to
the trapping construct, allowing a simpler positive selection with a pharmacological treatment
instead of cell sorting.
Construction and validation of trapping vectors
We built the triple fusion PGN by linking with a Ser-Gly spacer the PuroR, GFP and NTR elements,
and evaluated PGN efficiency by transient and stable transfection. Each element maintained its
functionality with a slight loss of efficiency in the triple fusion (5-10%), compared to the double
fusions (Supp. Fig. 1A). We subsequently treated stable PGN transfectants for different periods and
1
with different doses of either puromycin or MN. We observed that after treatment with low doses of
puromycin for a week, not all cells displayed detectable GFP fluorescence. This indicated that very
low levels of PGN expression are not sufficient to confer detectable fluorescence, but sufficient to
confer resistance to puromycin. Conversely, higher drug doses progressively increased the fraction
of fluorescent cells in a quick (2-3 days) and dose-dependent fashion, with the possibility to use
very high doses (20g/ml) to select cells expressing very high levels of PGN. As expected, MN
treatment of low puromycin-resistant cells counter-selected the brighter cells in a dose-dependent
manner, with selection efficacy progressively more effective with increased treatment duration (57days; Supp. Fig. 1B). This indicated that a combined use of low puromycin and high MN allows
selection of cells expressing PGN at very low levels. After the preliminary validation, we cloned
PGN between a strong cellular splice acceptor (SA) and a polyadenylation site (pA), obtaining the
‘Triple ACtivity Trap’ (TRACT) cassette. To overcome possible limits due to the presence of
backbone-specific integration “hot spots” in the genome (De et al. 2005; Wu et al. 2003), the
cassette was inserted into three different backbones: plasmidic, retroviral (Roberts et al. 1998) and
lentiviral(Follenzi et al. 2000), to obtain P-TRACT, R-TRACT and L-TRACT, respectively (Supp.
Fig. 1C). Initially, P-TRACT was tested on HEK-293T cells, because of their high transfection
efficiency. 106 cells were transfected with 105 molecules of linearized plasmid, and selected with
puromycin. Over 100 cell clones were counted, which confirmed that trapping events in basally
expressed genes can be promptly and efficiently isolated also from a plasmidic trap. The new
trapping cassette was inserted into retroviral and lentiviral backbones, and used in a wide screening
yielding 179 clones carrying integrations into genes transcriptionally regulated by HGF.
The screening strategy described here relies on a well-established functional genomics technique,
gene trapping (Gentile et al. 2003), and on a new selectable reporter, PGN. Despite being a triple
fusion protein, PGN retained good efficiency of each domain and allowed efficient positive and
negative pharmacological selection together with direct monitoring of expression by fluorescence
analysis. Interestingly, most traps selected for positive or negative response to HGF showed a
regulation of 1,5-2 fold, indicating that a modest transcriptional response to HGF is sufficient for
PGN to enable trap selection. In this view, possible applications of PGN as a selectable reporter
may extend beyond the gene trapping constructs described here. The flexibility and efficiency of the
PGN-based trap screening procedure make it suitable for wide surveys of transcriptionally regulated
genes, with two interesting features that render it complementary to microarray analysis: (i) gene
traps randomly integrate in the genome, virtually interrogating any transcriptionally active domain
of a cell, while microarrays interrogate a defined number of transcripts, exploring only a fraction of
the transcriptional potential of the genome (Katayama et al. 2005) and not considering antisense
transcription (Carninci et al. 2005); (ii) gene trapping generates reporter cell clones that can be used
in high-throughput screenings to identify upstream genes, or small molecules or peptides, that
modify the expression of the trapped gene.
2
Methods
The first step of PGN construction was the optimization of the design of double GFP-fusion
proteins, GFP-NTR and PuroR-GFP, as we have previously seen that the fusion between GFP and
NTR (GFNR) results in a slight loss of fluorescence and killing efficiency (10–15%; (Medico et al.
2001)). To generate an improved GFP-NTR fusion, we inserted a spacer of 15 aminoacids (3x SerGly-Gly- Gly-Gly) between GFP and NTR. To this aim, the NTR coding sequence was amplified
from pGFNR (Medico et al. 2001) using a sense primer containing the PstI restriction site followed
by the sequence coding for the Gly-Ser spacer and by the initial NTR coding sequence (5’AACTGCAGGAGGCGGTGGATCAGGCGGTGGAGGCTCTGGTGAAGGCGGTTCCGGAGG
CGGTTCAGCCATGGATATCATTTCTGTC-3’), and an antisense primer containing two
restriction sites (SacI and SpeI) and the 3’ NTR coding sequence (5’AGAGCTCACTAGTTTACACTTCGGTTAAGGT-3’). The PCR product was bluntized, digested
with PstI and introduced in a modified pEGFP-C1 (Clontech), previously digested with XhoI and
EcoRI, then bluntized and re-closed, downstream and in frame with the GFP coding sequence. The
new plasmid, called pGFNR2, resulted to be 5-10% more efficient than pGFNR (not shown). We
therefore decided to use the Gly-Ser linker also in the construction of the PuroR-GFP fusion, for
which the puromycin resistance gene (PuroR) was amplified by PCR from a PuroR-containing
plasmid
with
the
following
primers:
(i)
sense
primer:
5’CCAAGCTTAACCATGACCGAGTACAAGCCCACG-3’, and (ii) antisense primer (containing
the
3x
GlyGlyGlyGly-Ser
linker
sequence):
5’GGAATTCTGAACCTCCGCCACCTGAACCTCCGCCACCTGAACCTCCGCCACCGGCACC
GGGCTTGCGGGTC-3’.The PCR product was digested with HindIII and EcoRI enzymes and
cloned in pEGFP-C1, upstream and in frame with the GFP coding sequence. The new plasmid was
called pPURO-GFP. To obtaining the PGN triple fusion, the PuroR+linker sequence was excised
from pPURO-GFP and introduced into pGFNR2, upstream and in frame with the GFP-NTR coding
sequence. The new expression vector was called pPGN. All constructs were sequence-verified
before their use for transfection experiments. The trapping cassette (SA-PGN-PA) was constructed
by excising the SA sequence from p-SA--Gal (Friedrich and Soriano 1991) and inserting it
upstream of PGN in the pPGN plasmid, in substitution of the CMV promoter. The new plasmid was
called pSA-PGN. Subsequently, the bovine growth hormone poly(A) sequence was excised from pSA--Gal and inserted downstream from PGN in the pSA-PGN plasmid. The new plasmid,
containing the trapping cassette SA-PGN-PA, was called pP-TRACT. The lentiviral version of the
trap (pL-TRACT) was obtained by substituting the GFP gene and its PGK promoter in the
pRRL.SIN.cPPT.PGK.GFP (Follenzi et al. 2000), with the trapping cassette in reverse orientation
with respect to the vector. The retroviral version of the trap (pR-TRACT) was obtained exchanging
PGK.YFP of the MLV-based SIN retroviral vector pRkat43.3.PGK.YFP (Roberts et al. 1998), with
the trapping cassette in reverse orientation with respect to the vector. Viral traps were produced and
titrated according to standard procedures (De et al. 2005).
3
Mapping of trap integration sites by RAN-PCR
Rationale
We developed a new strategy to identify the genomic regions flanking the integrated gene trap. The
approach takes advance of the presence of repeat sequences in the genome (Alu for human, B2 for
mouse) to “anchor” PCR products containing the trap sequence. The strategy is therefore named
“Repeat-ANchored” PCR (RAN-PCR), and is performed on genomic DNA extracted from trap
clones. The advantage of this procedure over existing ones is that it does not require any enzymatic
reaction (digestion/ligation of the DNA, reverse transcription of the RNA) before PCR and is
therefore more amenable to high-throughput.
Methods
RAN-PCR is an improvement of the Alu-PCR protocol(Cole et al. 1991). By Alu-PCR, it is
possible to identify the vector integration sites performing a PCR on human genomic DNA with a
primer designed on the known vector sequence, and the other primer on the Alu sequences known
to be frequently repeated in the genome. The limit of this technique is a high number of aspecific
Alu-Alu amplification products. To overcome this limit, and to adapt the procedure to mouse
genomic DNA, we designed a new procedure, illustrated in Supplementary Figure 2, based on a
primer matching the B2 repeat, that is frequent in the mouse genome (Krayev et al. 1982), flanked
by a “suppression sequence” at its 5’. The primer containing the suppression sequence (underlined)
was
named
Supp-B2
and
had
the
following
sequence:
5’CTAATACGACTCACTATAGGGCGGCTGGTGAGATGGTTCAGT-3’. A second primer,
containing only the suppression sequence underlined above, was named Supp. The two antisense
primers designed on the viral vectors are: 5’-GCCTCAATAAAGCTTGCCTTG-3’, 5’TCCCAGGCTCAGATCTGGTCTAAC-3’, for the first PCR and the nested PCR respectively.
When B2-B2 amplification occurs, the resulting amplificates contain at both ends the suppression
sequence, which anneals intramolecularly forming a panhandle-like structure that can not be
amplified, greatly increasing the specificity of PCR amplification. Genomic DNA was extracted
from trapped cell clones using Blood & Cell Culture DNA Midi Kit (Qiagen). PCR reactions were
performed in a volume of 25 l with 250 ng of genomic DNA with 12.5 M antisense primer, 0,2
M Supp-B2 primer and 1 M Supp primer, using Advantage PCR mix (Clontech) with the
following cycles: 5x (94°C 10 sec, 66°C 10 sec, 72°C 3 min), 5x(94°C 10 sec, 70°C 10 sec, 72°C 3
min, 25x (94°C 10 sec, 68°C 10 sec, 72°C 3 min). 1 l of the PCR reaction was used as a template
for the nested PCR, with the same conditions but the nested antisense primer.
4
Supplementary References
Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, et al. (2005). The
transcriptional landscape of the mammalian genome. Science, 309, 1559-1563.
Cole CG, Goodfellow PN, Bobrow M and Bentley DR. (1991). Generation of novel sequence
tagged sites (STSs) from discrete chromosomal regions using Alu-PCR. Genomics, 10, 816-826.
De PM, Montini E, de Sio FR, Benedicenti F, Gentile A, Medico E and Naldini L. (2005). Promoter
trapping reveals significant differences in integration site selection between MLV and HIV vectors
in primary hematopoietic cells. Blood, 105, 2307-2315.
Follenzi A, Ailles LE, Bakovic S, Geuna M and Naldini L. (2000). Gene transfer by lentiviral
vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet, 25, 217222.
Friedrich G and Soriano P. (1991). Promoter traps in embryonic stem cells: a genetic screen to
identify and mutate developmental genes in mice. Genes Dev, 5, 1513-1523.
Gentile A, D'Alessandro L and Medico E. (2003). Gene trapping: a multi-purpose tool for
functional genomics. Biotechnol Genet Eng Rev, 20, 77-100.
Katayama S, Tomaru Y, Kasukawa T, Waki K, Nakanishi M, Nakamura M, Nishida H, Yap CC,
Suzuki M, Kawai J, Suzuki H, Carninci P, Hayashizaki Y, Wells C, Frith M, Ravasi T, Pang KC,
Hallinan J, Mattick J, Hume DA, Lipovich L, Batalov S, Engstrom PG, Mizuno Y, Faghihi MA,
Sandelin A, Chalk AM, Mottagui-Tabar S, Liang Z, Lenhard B and Wahlestedt C. (2005).
Antisense transcription in the mammalian transcriptome. Science, 309, 1564-1566.
Krayev AS, Markusheva TV, Kramerov DA, Ryskov AP, Skryabin KG, Bayev AA and Georgiev
GP. (1982). Ubiquitous transposon-like repeats B1 and B2 of the mouse genome: B2 sequencing.
Nucleic Acids Res, 10, 7461-7475.
Medico E, Gambarotta G, Gentile A, Comoglio PM and Soriano P. (2001). A gene trap vector
system for identifying transcriptionally responsive genes. Nat Biotechnol, 19, 579-582.
Medico E, Mongiovi AM, Huff J, Jelinek MA, Follenzi A, Gaudino G, Parsons JT and Comoglio
PM. (1996). The tyrosine kinase receptors Ron and Sea control "scattering" and morphogenesis of
liver progenitor cells in vitro. Mol Biol Cell, 7, 495-504.
Roberts MR, Cooke KS, Tran AC, Smith KA, Lin WY, Wang M, Dull TJ, Farson D, Zsebo KM
and Finer MH. (1998). Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric
immune receptors bearing zeta or gamma signaling domains. J Immunol, 161, 375-384.
Wu X, Li Y, Crise B and Burgess SM. (2003). Transcription start regions in the human genome are
favored targets for MLV integration. Science, 300, 1749-1751.
5